193 results about "Indolamines" patented technology

Presently provided are methods for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of a compound as described in one of the aspects described herein; (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound as described in one of the aspects described herein; (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; and (f) treating immunosuppression associated with an infectious disease, e.g., HIV-I infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount a compound as described in one of the aspects described herein.

Presently provided are IDO inhibitors of general formulae (VII), (VIII) as shown below and pharmaceutical compositions thereof, useful for modulating an activity of indoleamine 2,3-dioxygenase; treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression; treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; treating tumor-specific immunosuppression associated with cancer; and treating immunosupression associated with an infectious disease.

The present invention is directed to N-hydroxyamidino compounds which are modulators of indoleamine 2,3-dioxygenase (IDO), as well as compositions and pharmaceutical methods thereof.

The present application is directed to processes and intermediates for making 4-({2-[(aminosulfonyl)amino]ethyl}amino)-N-(3-bromo-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide, which is an inhibitor of indoleamine 2,3-dioxygenase, useful in the treatment of cancer and other disorders.

Presently provided are compounds according to the formula (I) or (II), and pharmaceutical compositions comprising the compounds, wherein R1, R4, and R5 are defined herein. Such compounds and compositions are useful for modulating an activity of indoleamine 2,3-dioxygenase; treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression; treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine -2,3-dioxygenase; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; treating tumor-specific immunosuppression associated with cancer; and treating immunosupression associated with an infectious disease.

The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a selective inhibitor of indoleamine 2, 3-dioxygenase 1 (IDO1), and the use of the combination therapies for the treat-ment of cancer, and in particular for treating cancers that express PD-L 1.

Disclosed herein are 5 or 8-substituted imidazo[1,5-a]pyridines and pharmaceutical compositions comprising at least one such 5 or 8-substituted imidazo[1,5-a]pyridines, processes for the preparation thereof, and the use thereof in therapy. Disclosed herein are certain 5 or 8-substituted imidazo[1,5-a]pyridines that can be useful for inhibiting indoleamine 2,3-dioxygenase and / or tryptophane 2,3-dioxygenase and for treating diseases or disorders mediated thereby.

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

The invention discloses an application of azatryptanthrin derivatives as IDO1 (indoleamine 2,3-dioxygenase) and / or TDO (tryptophan 2,3-dioxygenase) inhibitors. The structure of the derivatives is shown as the general formula (I) in the description, wherein substituents are defined in detail in the description. The compounds shown as the general formula (I) have an inhibition effect on IDO1 and / or TDO and can be used for treating diseases having pathological characteristics of IDO1 and / or TDO mediated tryptophan metabolism, and the diseases include but are not limited to tumors, autoimmune diseases, infectious diseases, Alzheimer disease, depression and anxiety disorder.

The invention belongs to the technical field of medicines and particularly relates to a compound represented by a formula I (shown in the description) as well as pharmaceutically acceptable salt and stereisomer of the compound. X, Y, Z, R1, R2, R3, R1a, R2a, m and N in the formula I are defined in the description. The invention further relates to pharmaceutical preparations, pharmaceutical compositions of the compounds and use of the pharmaceutical preparations and the pharmaceutical compositions in preparation of drugs for treating related diseases abnormally medicated by indoleamine 2,3-dioxygenase (IDO).

There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3 -dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and / or inflammatory disorders utilizing the compounds of the invention.

There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and / or inflammatory disorders utilizing the compounds of the invention.

The invention relates to the field of drugs, in particular to a carbamidine derivative containing a furan structure and a composition of the carbamidine derivative. The derivative and the compositionthereof can be used for preparing drugs for treating a pathologic characteristic disease with an indoleamine 2,3-dioxygenase mediated tryptophan metabolic pathway. The invention further relates to a method for preparing the derivative and an intermediate thereof.

The invention discloses a spiro compound taking as an indoleamine-2, 3-dioxygenase inhibitor, and a preparation method thereof. The structure of the inhibitor is represented by general formula I, wherein Ar, E, Y, X, C, D, W, B, ring A and ring B are defined in the patent specification and claims. The compound with the general formula I can be taken as an indoleamine-2, 3-dioxygenase inhibitor inpreparation of medicines used for preventing and / or treating indoleamine-2, 3-dioxygenase mediated diseases.

The invention discloses the use of azatryptanthin derivatives as IDO1 and / or TDO inhibitors. The derivatives are represented by the general formula (I), wherein the definition of each substituent is detailed in the description. The compound represented by the general formula (I) has inhibitory effect on indoleamine-2,3-dioxygenase 1 (IDO1) and / or tryptophan-2,3-dioxygenase (TDO), and can be used For the treatment of diseases with pathological features of tryptophan metabolism mediated by IDO1 and / or TDO, including but not limited to tumors, autoimmune diseases, infectious diseases, Alzheimer's disease, depression, anxiety.

The invention discloses two novel anthraquinone compounds, namely Anthrininones B and C, as well as a preparation method and application thereof in preparing protein-tyrosine-phosphatase (PTPs) and indole-amine 2,3-dioxygenase 1 (IDO1) inhibitors, and further discloses application of 6-O-methylalaternin in preparing the PTPs and the IDO1 inhibitors, and application of Anthrininone A in preparing the IDO1 inhibitors. The compounds Anthrininones B and C have structural formulae (I) shown in the specification. The compounds Anthrininones B and C and 6-O-methylalaternin are separated from a fermentation liquid of Alternaria tenuissma JX156349, and can be applied to study on lead compounds of PTP inhibitors and DIO1 inhibitors.

The invention relates to a compound, which is one or a plurality of indoleamine 2,3-dioxygenase inhibitors. The present invention further provides a pharmaceutical component containing the compound, apreparation containing the compound, and uses of the indoleamine 2,3-dioxygenase inhibitors, wherein the compound can be used for treating indoleamine 2,3-dioxygenase related symptoms through singlemedication or combination with other drugs.

There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compound and methods of treating proliferative disorders, such as cancer, viral infections and / or inflammatory disorders utilizing the compounds of the invention.

A composition and method for using a composition, the composition having at least two compounds, each of which induces indolamine 2,3-dioxygenase, for the treatment of an autoimmune disorder or disease or immune rejection of transplants or gene therapeutically modified cells, wherein the inducers have different mechanism of action and wherein the composition gives rise to a synergistic effect on the IDO levels.